The scale of individual prognosis in patients PHC takes into account both clinical and histopathological tumor characteristics. This scale may be useful to optimize the individual treatment.
Background: Pancreatogenic splenic pseudocysts are a relatively rare condition. Intra-splenic localization
is of the splenic pseudocysts is dangerous because of the possibility of massive haemorrhage and organ
rupture.
Aim: To analyse our experience in the diagnosis and treatment of pancreatogenic pseudocysts of the spleen.
Materials and Methods: The analysis of the short and long-term results of treatment of the 34 patients with
pancreatogenic splenic pseudocysts (extrapancreatic localization) (1985-2019) was performed. In the study,
the majority of male patients - 88.2%, the age of patients was 45 ± 7 years.
Results: Percutaneous drainage under US-control was performed in 11 (32.4%) patients, distal pancreatic
resection with splenectomy was performed in 23 (67.6%) in the cases of pancreatic tail calcific pancreatitis.
In all cases of percutaneous treatment, a high level of amylase was found in the fluid from pseudocysts.
Bacteriological confirmation of the growth of any bacteria in the content was not obligatory. Suppuration
of the fluid of the pseudocyst was observed in 85.3% of the cases.
Conclusion: Pancreatogenic pseudocysts of the spleen are one of the complications of destructive
pancreatitis. They can remain undiagnosed for a long time, become infected and aggravate the course of the
disease. They are often the cause of the development of sepsis and peritonitis due to the rupture of the organ
capsule and bleeding into the abdominal cavity. The use of percutaneous minimally invasive methods of
treatment for intra-organ pancreatogenic pseudocysts makes it possible to improve the results of treatment
in this group of patients, and also, in the optimal case, be the final method of treatment.
The small remnant liver volume remains an urgent problem in liver resection surgery. The use of the method of twostage liver resection – the Associated Liver Partition and Portal vein ligation for Staged hepatectomy in most cases allows to solve this problem. However, this method is associated with a number of complications and limitations. The presented clinical observation shows the effectiveness of an alternative version of this technology – radiofrequency ablation of the liver parenchyma in the plane of the proposed resection with ligation of the right branch of the portal vein to increase the volume of the estimated liver remnant in intrahepatic cholangiocellular cancer.
Aim. To improve the treatment outcomes, quality and life expectancy, prognosis in patients with hepatocellular carcinoma based on an analysis of treatment outcomes.Materials and methods. The analysis of the long-term results of treatment of 114 patients with hepatocellular carcinoma for 2015–2020 was carried out. Two groups of patients were distinguished: 41 (35.9%) patients were included in group I (a potentially resectable tumor with R0 surgery), and 63 (55.2%) patients were included in group II (advanced tumor does not suggest R0 resection).Results. Actuarial survival for patients with R0 surgery (48) was: 1 year – 85%, 3 years – 65%, 5 years – 55%; in patients with unresectable tumor after transarterial chemoembolization: 1 year – 65%, 3 years – 29%, 5 years – 11%; after local destruction methods – 0.5 years – 75%, 1 year – 36%, 1.5 years – 22%.Conclusions. The results of treatment of patients with hepatocellular carcinoma confirm the feasibility and effectiveness of a rational multidisciplinary approach. It allows you to achieve satisfactory results in multidisciplinary hospitals. The results are consistent with the data of large surgical centers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.